Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the coronavirus disease in 2019 (COVID-19) which rapidly evolved from an outbreak in Wuhan, China into a pandemic that has resulted in over millions of infections and over hundreds of thousands of mortalities worldwide. Various coagulopathies have been reported in association with COVID-19, including disseminated intravascular coagulation (DIC), sepsis-induced coagulopathy (SIC), local microthrombi, venous thromboembolism (VTE), arterial thrombotic complications, and thrombo-inflammation. There is a plethora of publications and conflicting data on hematological and hemostatic derangements in COVID-19 with some data suggesting the link to disease progress, severity and/or mortality. There is also growing evidence of potentially useful clinical biomarkers to predict COVID-19 progression and disease outcomes. Of those, a link between thrombocytopenia and COVID-19 severity or mortality was suggested. In this opinion report, we examine the published evidence of hematological and hemostatic laboratory derangements in COVID-19 and the interrelated SARS-CoV-2 induced inflammation.
Keywords: biochemistry; new coronary pneumonia; hematology; SARS-CoV-2.
Title: Guidelines on Biochemical/Hematological Monitoring of COVID-19 Patients
Author: Yasir.A.Ahmed, Ayeed Marfo AlEnizi, Mansour Farhan AlEnizi, Fahad Mohammed AlWallan
International Journal of Healthcare Sciences
ISSN 2348-5728 (Online)
Vol. 10, Issue 1, April 2022 - September 2022
Page No: 90-99
Research Publish Journals
Website: www.researchpublish.com
Published Date: 28-June-2022
